摘要
目的研究柠檬酸合成酶(CS)在乳腺癌组织及正常乳腺组织中的表达,分析其表达与临床病理特征的关系。方法通过蛋白质免疫印迹技术检测乳腺癌组织与癌旁组织中的CS蛋白表达水平,免疫组化技术检测乳腺癌组织芯片中的CS表达情况,分析CS的表达水平与临床病理特征的关系,分析Cancer Genome Atlas(TCGA)数据库中CS的表达水平与乳腺癌患者生存期的关系。结果乳腺癌患者组织中CS蛋白表达显著上调(P=0.028),CS蛋白表达与乳腺癌的组织学分级(P=0.035)、临床分期(P<0.001)、是否淋巴结转移(P<0.001)相关,CS高表达的乳腺癌患者的生存率显著降低(P=0.007)。结论 CS在乳腺癌组织中表达上调,与乳腺癌的进展与临床预后相关,有望成为乳腺癌新的生物标记物。
Objective To investigate the expression of citrate synthase in breast cancer tissues andnon-cancerous tissues,and analyze the associations of its expression and clinical pathological features.Methods Western blot was used to detect the protein level of CS in breast cancer tissues and non-cancerous tissues. Immunohistochemistry was used to detect the expression of CS in breast cancer tissuemicroarrays. The associations of CS expression and clinical pathological features were analyzed. Therelationship between CS expression and survival period of breast cancer patients in Cancer GenomeAtlas(TCGA)database was analyzed. Results The expression level of CS protein was significantlyup-regulated in breast cancer patients(P=0.028). The expression of CS protein was correlated withhistological grade(P=0.035),clinical stage(P〈0.001),and lymph node metastasis(P〈0.001). Thesurvival rate of breast cancer patients with high CS expression was significantly reduced(P=0.007).Conclusion Our study showed that up-regulation of CS in breast cancer is related to the progression ofbreast cancer and its clinical prognosis. It is expected to be a new biomarker for breast cancer.
作者
何广宁
蔡志煅
邓润枢
温润耀
邓丁梅
张爱玲
HE Guangning;CAI Zhiduan;DENG Runshu;WEN Runyao;DENG Dingmei;ZHANG Ailing(Department of Breast,Dongguan People's Hospital,Dongguan 523059,China;Guangzhou First People's Hospital,Guangzhou 510180,China)
出处
《岭南现代临床外科》
2018年第3期257-260,共4页
Lingnan Modern Clinics in Surgery
基金
广东省医学科学技术研究基金(A2018195)